CN105477113A - Pharmaceutical composition for treating cerebral stroke - Google Patents

Pharmaceutical composition for treating cerebral stroke Download PDF

Info

Publication number
CN105477113A
CN105477113A CN201610017031.7A CN201610017031A CN105477113A CN 105477113 A CN105477113 A CN 105477113A CN 201610017031 A CN201610017031 A CN 201610017031A CN 105477113 A CN105477113 A CN 105477113A
Authority
CN
China
Prior art keywords
parts
radix
pharmaceutical composition
caulis
herba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610017031.7A
Other languages
Chinese (zh)
Inventor
魏秀芝
管清华
张阳
陈晓璐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610017031.7A priority Critical patent/CN105477113A/en
Publication of CN105477113A publication Critical patent/CN105477113A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/486—Millettia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/533—Leonurus (motherwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605—Morus (mulberry)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/716—Clematis (leather flower)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a pharmaceutical composition for treating a cerebral stroke. The pharmaceutical composition is prepared from, by weight, 15-25 parts of peach kernels, 15-25 parts of radix salviae miltiorrhizae, 10-20 parts of fructus xanthii, 10-25 parts of semen vaccariae, 10-15 parts of leaves of henon bamboo, 10-15 parts of acorus tatarinowii, 10-15 parts of reed rhizome, 10-15 parts of radix paeoniae rubra, 5-10 parts of barberry roots, 10-25 parts of Japanese honeysuckle stems, 10-25 parts of motherwort fruit, 10-30 parts of seman platycladi, 10-20 parts of tea tree roots, 10-30 parts of herb of twinleaf zornia, 10-30 parts of scandent schefflera stems and leaves, 5-10 parts of roots of kirilow rhodiola, 5-10 parts of rhizoma curcumae, 5-10 parts of ramulus mori, 5-10 parts of herba centellae, 15-30 parts of caulis spatholobi, 15-30 parts of ovateleaf holly bark and 5-15 parts of radix clematidis. The pharmaceutical composition has the effects of tonifying Qi, activating the blood, removing blood stasis, dredging collaterals, dispelling pathogenic wind, eliminating phlegm and clearing away heat to inhibit wind and is used for treating symptoms such as hemiplegia, numbness of the limbs, alalia and facial paralysis caused by the stroke, the toxic and side effects do not exist, and the treatment effect is significant.

Description

A kind of pharmaceutical composition for the treatment of apoplexy
Technical field
The present invention relates to a kind of pharmaceutical composition, in particular to a kind of pharmaceutical composition for the treatment of apoplexy.
Background technology
Apoplexy and acute cerebrovascular disease, be also called apoplexy or apoplexy, it is the brain limitation disturbance of blood circulation that the neck arteries pathological changes of brain or domination brain causes, primary disease great majority occur in above middle age, it is common complaint among the elderly, frequently-occurring disease, the common feature of apoplexy is that onset is hurried, often brain damage peaks at short notice, if patient survival, there is hemiplegia more, the sequela such as aphasia, its sickness rate and disability rate are all very high, China newly sends out completeness brain apoplexy 120-150 ten thousand people every year, died 80-100 ten thousand people, in survivor, about 75% disables, in 5 years, relapse rate is up to 41%.
Apoplexy is deficiency in origin and excess in superficiality, the disease of upper excess and lower deficiency.Acute stage, mark case of a physically strong patient running a high fever shape was more outstanding, symptomatic treatment in acute condition, therefore modern treatment mostly is doctor trained in Western medicine symptomatic treatment, chronic phase, treatment, when to get rid of evils, commonly used suppressing the hyperactive liver to relieve the wind syndrome mainly based on Chinese medicine, removing heat-phlegm, reduce phlegm purging FU-organs, eleminating phlegm and freeing channels, the Therapeutic Method such as consciousness and resuscitation restoring, convalescent period mostly is deficiency and excess and adds assorted, and the domination of pathogen is unclear and weakened body resistance existing, controls suitable strengthening vital QI to eliminate pathogenic factors, conventional nourishing YIN relieves dizziness, high fever, infantile convulsions, epilepsy, etc., the methods such as benefiting QI for activating blood circulation.
Summary of the invention
The invention provides a kind of pharmaceutical composition for the treatment of apoplexy, there is effect of benefiting QI for activating blood circulation, disperse blood stasis and dredge collateral, dispelling pathogenic wind and eliminating phlegm, clearing away heat and relieving the wind syndrome, be used for the treatment of the diseases such as hemiplegia caused by apoplexy, numb limbs and tense tendons, slurred speech, facial hemiparalysis, have no side effect, therapeutic effect is remarkable.
The concrete technical scheme of the present invention is that a kind of pharmaceutical composition for the treatment of apoplexy, is made up of the crude drug of following weight portion: Semen Persicae, Radix Salviae Miltiorrhizae, Fructus Xanthii.
In the present invention's specific embodiment, described a kind of pharmaceutical composition for the treatment of apoplexy is made up of the crude drug of following weight portion: Semen Persicae 15-25 part, Radix Salviae Miltiorrhizae 15-25 part, Fructus Xanthii 10-20 part.
In the present invention's specific embodiment, described a kind of pharmaceutical composition for the treatment of apoplexy is made up of the crude drug of following weight portion: Semen Persicae 15-25 part, Radix Salviae Miltiorrhizae 15-25 part, Fructus Xanthii 10-20 part, Semen Vaccariae 10-25 part, Herba Lophatheri 10-15 part, Rhizoma Acori Graminei 10-15 part, Rhizoma Phragmitis 10-15 part, Radix Paeoniae Rubra 10-15 part, Radix Berberidis 5-10 part, Caulis Lonicerae 10-25 part, Fructus Leonuri 10-25 part, Semen Platycladi 10-30 part, Radix Camelliae sinensis 10-20 part, Herba Zornia Diphyllae 10-30 part, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 10-30 part, Radix Rhodiolae 5-10 part, Rhizoma Curcumae 5-10 part, Ramulus Mori 5-10 part, Herba Centellae 5-10 part, Caulis Spatholobi 15-30 part, Cortex Ilicis Rotundae 15-30 part, Radix Clematidis 5-15 part.
In the present invention's specific embodiment, described a kind of pharmaceutical composition for the treatment of apoplexy is made up of the crude drug of following weight portion: 20 parts, Semen Persicae, Radix Salviae Miltiorrhizae 20 parts, Fructus Xanthii 15 parts, Semen Vaccariae 20 parts, Herba Lophatheri 13 parts, Rhizoma Acori Graminei 13 parts, Rhizoma Phragmitis 13 parts, Radix Paeoniae Rubra 13 parts, Radix Berberidis 8 parts, Caulis Lonicerae 18 parts, Fructus Leonuri 18 parts, Semen Platycladi 20 parts, Radix Camelliae sinensis 15 parts, Herba Zornia Diphyllae 20 parts, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 20 parts, Radix Rhodiolae 8 parts, Rhizoma Curcumae 8 parts, Ramulus Mori 7 parts, Herba Centellae 7 parts, Caulis Spatholobi 20 parts, Cortex Ilicis Rotundae 22 parts, Radix Clematidis 10 parts.
In the present invention's specific embodiment, described a kind of pharmaceutical composition for the treatment of apoplexy is made up of the crude drug of following weight portion: 17 parts, Semen Persicae, Radix Salviae Miltiorrhizae 21 parts, Fructus Xanthii 12 parts, Semen Vaccariae 24 parts, Herba Lophatheri 11 parts, Rhizoma Acori Graminei 14 parts, Rhizoma Phragmitis 12 parts, Radix Paeoniae Rubra 15 parts, Radix Berberidis 6 parts, Caulis Lonicerae 23 parts, Fructus Leonuri 15 parts, Semen Platycladi 28 parts, Radix Camelliae sinensis 16 parts, Herba Zornia Diphyllae 27 parts, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 17 parts, Radix Rhodiolae 6 parts, Rhizoma Curcumae 9 parts, Ramulus Mori 5 parts, Herba Centellae 10 parts, Caulis Spatholobi 29 parts, Cortex Ilicis Rotundae 26 parts, Radix Clematidis 14 parts.
In the present invention's specific embodiment, described a kind of pharmaceutical composition for the treatment of apoplexy is made up of the crude drug of following weight portion: 23 parts, Semen Persicae, Radix Salviae Miltiorrhizae 16 parts, Fructus Xanthii 18 parts, Semen Vaccariae 12 parts, Herba Lophatheri 14 parts, Rhizoma Acori Graminei 11 parts, Rhizoma Phragmitis 15 parts, Radix Paeoniae Rubra 10 parts, Radix Berberidis 8 parts, Caulis Lonicerae 12 parts, Fructus Leonuri 22 parts, Semen Platycladi 26 parts, Radix Camelliae sinensis 18 parts, Herba Zornia Diphyllae 27 parts, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 25 parts, Radix Rhodiolae 9 parts, Rhizoma Curcumae 8 parts, Ramulus Mori 10 parts, Herba Centellae 7 parts, Caulis Spatholobi 27 parts, Cortex Ilicis Rotundae 24 parts, Radix Clematidis 14 parts.
The present invention provides a kind of preparation method for the treatment of the pharmaceutical composition of apoplexy on the other hand, comprises the following steps:
(1) Rhizoma Acori Graminei steam distillation extracts volatile oil, obtains mixture of volatile oil, and it is for subsequent use to collect aqueous solution;
(2) Radix Salviae Miltiorrhizae, Fructus Xanthii, Herba Lophatheri, Radix Berberidis, Semen Platycladi, Herba Zornia Diphyllae, Radix Rhodiolae, Ramulus Mori, Cortex Ilicis Rotundae, Radix Clematidis add soak by water 2-3 time accounting for gross weight 8-15 times amount, each 1.5-2 hour, collecting decoction, add the aqueous solution that step (1) obtains again, filter, relative density when filtrate is concentrated into 80 DEG C is the extractum (I) of 1.15-1.25;
(3) Semen Persicae, Semen Vaccariae, Rhizoma Curcumae, Rhizoma Phragmitis, Radix Paeoniae Rubra, Caulis Lonicerae, Fructus Leonuri, Radix Camelliae sinensis, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae), Herba Centellae, Caulis Spatholobi are added account for gross weight 8-15 times amount 85% alcoholic solution in extract 2-3 time, each 2-3 hour, filter, merging filtrate, placement is spent the night, reclaim ethanol, relative density when filtrate being concentrated into 60 DEG C is the extractum (II) of 1.15-1.25;
(4) by step (2), the mixing of (3) gained extractum, dry, and in add the volatile oil of step (1), stir, to obtain final product.
In a specific embodiment of the present invention, described preparation method, wherein adds the soak by water 3 times accounting for gross weight 10 times amount, each 1.5 hours in step (2); Account in step (3) in the alcoholic solution of 85% of gross weight 10 times amount and extract 2 times, each 3 hours.
The pharmaceutical composition for the treatment of apoplexy of the present invention, can prepare according to the conventional method of the field of Chinese medicines, comprises soak by water, by each crude drug pulverize etc.Also the conventional method of Chinese medicine preparation can be adopted to be prepared into any traditional oral preparation.Described oral formulations is capsule, pill, powder, tablet, granule etc.
The present invention has following advantages and beneficial effect: pharmaceutical composition of the present invention has effect of benefiting QI for activating blood circulation, disperse blood stasis and dredge collateral, dispelling pathogenic wind and eliminating phlegm, clearing away heat and relieving the wind syndrome, be used for the treatment of the diseases such as hemiplegia caused by apoplexy, numb limbs and tense tendons, slurred speech, facial hemiparalysis, have no side effect, therapeutic effect is remarkable.
Detailed description of the invention
Embodiment 1:
Treat a pharmaceutical composition for apoplexy, be made up of the crude drug of following weight portion: 20 parts, Semen Persicae, Radix Salviae Miltiorrhizae 20 parts, Fructus Xanthii 15 parts, Semen Vaccariae 20 parts, Herba Lophatheri 13 parts, Rhizoma Acori Graminei 13 parts, Rhizoma Phragmitis 13 parts, Radix Paeoniae Rubra 13 parts, Radix Berberidis 8 parts, Caulis Lonicerae 18 parts, Fructus Leonuri 18 parts, Semen Platycladi 20 parts, Radix Camelliae sinensis 15 parts, Herba Zornia Diphyllae 20 parts, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 20 parts, Radix Rhodiolae 8 parts, Rhizoma Curcumae 8 parts, Ramulus Mori 7 parts, Herba Centellae 7 parts, Caulis Spatholobi 20 parts, Cortex Ilicis Rotundae 22 parts, Radix Clematidis 10 parts;
Each crude drug is dry at 45 DEG C, be cooled to room temperature, pulverize state, and mix homogeneously, load snap fit capsule, to obtain final product.
Embodiment 2:
Treat a pharmaceutical composition for apoplexy, be made up of the crude drug of following weight portion: 20 parts, Semen Persicae, Radix Salviae Miltiorrhizae 20 parts, Fructus Xanthii 15 parts, Semen Vaccariae 20 parts, Herba Lophatheri 13 parts, Rhizoma Acori Graminei 13 parts, Rhizoma Phragmitis 13 parts, Radix Paeoniae Rubra 13 parts, Radix Berberidis 8 parts, Caulis Lonicerae 18 parts, Fructus Leonuri 18 parts, Semen Platycladi 20 parts, Radix Camelliae sinensis 15 parts, Herba Zornia Diphyllae 20 parts, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 20 parts, Radix Rhodiolae 8 parts, Rhizoma Curcumae 8 parts, Ramulus Mori 7 parts, Herba Centellae 7 parts, Caulis Spatholobi 20 parts, Cortex Ilicis Rotundae 22 parts, Radix Clematidis 10 parts;
Take said medicine by formula ratio, be added to the water, boil, slow fire boiling 30 minutes, filter, filtering residue adds water again, slow fire boiling 30 minutes, merge twice medicinal liquid, to obtain final product.
Embodiment 3:
Treat a pharmaceutical composition for apoplexy, be made up of the crude drug of following weight portion: 20 parts, Semen Persicae, Radix Salviae Miltiorrhizae 20 parts, Fructus Xanthii 15 parts, Semen Vaccariae 20 parts, Herba Lophatheri 13 parts, Rhizoma Acori Graminei 13 parts, Rhizoma Phragmitis 13 parts, Radix Paeoniae Rubra 13 parts, Radix Berberidis 8 parts, Caulis Lonicerae 18 parts, Fructus Leonuri 18 parts, Semen Platycladi 20 parts, Radix Camelliae sinensis 15 parts, Herba Zornia Diphyllae 20 parts, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 20 parts, Radix Rhodiolae 8 parts, Rhizoma Curcumae 8 parts, Ramulus Mori 7 parts, Herba Centellae 7 parts, Caulis Spatholobi 20 parts, Cortex Ilicis Rotundae 22 parts, Radix Clematidis 10 parts;
Preparation method comprises the following steps:
(1) Rhizoma Acori Graminei steam distillation extracts volatile oil, obtains mixture of volatile oil, and it is for subsequent use to collect aqueous solution;
(2) Radix Salviae Miltiorrhizae, Fructus Xanthii, Herba Lophatheri, Radix Berberidis, Semen Platycladi, Herba Zornia Diphyllae, Radix Rhodiolae, Ramulus Mori, Cortex Ilicis Rotundae, Radix Clematidis add soak by water 2-3 time accounting for gross weight 8-15 times amount, each 1.5-2 hour, collecting decoction, add the aqueous solution that step (1) obtains again, filter, relative density when filtrate is concentrated into 80 DEG C is the extractum (I) of 1.15-1.25;
(3) Semen Persicae, Semen Vaccariae, Rhizoma Curcumae, Rhizoma Phragmitis, Radix Paeoniae Rubra, Caulis Lonicerae, Fructus Leonuri, Radix Camelliae sinensis, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae), Herba Centellae, Caulis Spatholobi are added account for gross weight 8-15 times amount 85% alcoholic solution in extract 2-3 time, each 2-3 hour, filter, merging filtrate, placement is spent the night, reclaim ethanol, relative density when filtrate being concentrated into 60 DEG C is the extractum (II) of 1.15-1.25;
(4) by step (2), the mixing of (3) gained extractum, dry, and in add the volatile oil of step (1), stir, incapsulate and get final product.
Embodiment 4:
Treat a pharmaceutical composition for apoplexy, be made up of the crude drug of following weight portion: 17 parts, Semen Persicae, Radix Salviae Miltiorrhizae 21 parts, Fructus Xanthii 12 parts, Semen Vaccariae 24 parts, Herba Lophatheri 11 parts, Rhizoma Acori Graminei 14 parts, Rhizoma Phragmitis 12 parts, Radix Paeoniae Rubra 15 parts, Radix Berberidis 6 parts, Caulis Lonicerae 23 parts, Fructus Leonuri 15 parts, Semen Platycladi 28 parts, Radix Camelliae sinensis 16 parts, Herba Zornia Diphyllae 27 parts, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 17 parts, Radix Rhodiolae 6 parts, Rhizoma Curcumae 9 parts, Ramulus Mori 5 parts, Herba Centellae 10 parts, Caulis Spatholobi 29 parts, Cortex Ilicis Rotundae 26 parts, Radix Clematidis 14 parts;
Take said medicine by formula ratio, be added to the water, boil, slow fire boiling 30 minutes, filter, filtering residue adds water again, slow fire boiling 30 minutes, merge twice medicinal liquid, to obtain final product.
Embodiment 5:
Treat a pharmaceutical composition for apoplexy, be made up of the crude drug of following weight portion: 23 parts, Semen Persicae, Radix Salviae Miltiorrhizae 16 parts, Fructus Xanthii 18 parts, Semen Vaccariae 12 parts, Herba Lophatheri 14 parts, Rhizoma Acori Graminei 11 parts, Rhizoma Phragmitis 15 parts, Radix Paeoniae Rubra 10 parts, Radix Berberidis 8 parts, Caulis Lonicerae 12 parts, Fructus Leonuri 22 parts, Semen Platycladi 26 parts, Radix Camelliae sinensis 18 parts, Herba Zornia Diphyllae 27 parts, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 25 parts, Radix Rhodiolae 9 parts, Rhizoma Curcumae 8 parts, Ramulus Mori 10 parts, Herba Centellae 7 parts, Caulis Spatholobi 27 parts, Cortex Ilicis Rotundae 24 parts, Radix Clematidis 14 parts;
Each crude drug is dry at 45 DEG C, be cooled to room temperature, pulverize state, and mix homogeneously, load snap fit capsule, to obtain final product.
Embodiment 6: the impact that pharmaceutical composition of the present invention is formed thrombus in vivo
Get Kunming mouse 50, male, body weight 22g ± 2g, be divided into 5 groups by body weight stratified random, dosage group (2.5g crude drug/kg), low dose group of the present invention (1g crude drug/kg) and compound Salviae Miltiorrhizae group (2g/kg) in blank group, high dose group of the present invention (8g crude drug/kg), the present invention, often organize 10, administration volume is 20ml/kg, blank group gives the NS of equivalent, every day 1 time, for three days on end.After last administration 1 hour, tail vein injection collagen protein and adrenergic intermixture, observed the recovery number of hemiplegia in mice 15 minutes.Result of the test is in table 1.
The impact that table 1 pharmaceutical composition of the present invention is formed thrombus in vivo
Group Number of animals (only) Recover number (only)
Matched group 10 0
Low dose group of the present invention 10 3
Dosage group in the present invention 10 6
High dose group of the present invention 10 9
Compound Salviae Miltiorrhizae group 10 9
Above-mentioned experimental result shows, pharmaceutical composition of the present invention obviously can reduce the mice thrombotic hemiplegia symptom brought out by collagen protein and epinephrine, illustrates that it is formed with certain inhibitory action to thrombus in vivo.
Embodiment 7: the clinical observation on the therapeutic effect of Chinese medicine composition of the present invention
1, physical data
Selection of clinical patient 200 example, wherein man 110 example, female 90 example, 50-70 year, all patients meet the sick diagnostic criteria of apoplexy, and Western medicine diagnose is cerebral infarction.
2, Therapeutic Method
Adopt the capsule made of embodiment 1, every containing crude drug 1g, every day is early, middle and late respectively takes one to patient, within 4 weeks, is a course for the treatment of, minimumly takes 3 courses for the treatment of.
3, curative effect determinate standard
Curative effect is evaluated by the sick scoring method of apoplexy, adopts nimodipine method [before (before treatment the rear integration of integration-treatment)/treatment integration] × 100%.
Recovery from illness: >=85%, symptom disappears substantially;
Effective: >=50%, symptom obviously changes;
Effective: >=20%, symptom makes moderate progress;
Invalid: < 20%, symptom is without improvement.
4, therapeutic outcome
After 3 courses for the treatment of, cure 32 examples, effective 122 examples, effective 40 examples, invalid 6 examples, total effective rate 97%, all there is not untoward reaction in all cases.

Claims (8)

1. treat a pharmaceutical composition for apoplexy, be made up of the crude drug of following weight portion: Semen Persicae, Radix Salviae Miltiorrhizae, Fructus Xanthii.
2. a kind of pharmaceutical composition for the treatment of apoplexy according to claim 1, is made up of the crude drug of following weight portion: Semen Persicae 15-25 part, Radix Salviae Miltiorrhizae 15-25 part, Fructus Xanthii 10-20 part.
3. a kind of pharmaceutical composition for the treatment of apoplexy according to claim 1, be made up of the crude drug of following weight portion: Semen Persicae 15-25 part, Radix Salviae Miltiorrhizae 15-25 part, Fructus Xanthii 10-20 part, Semen Vaccariae 10-25 part, Herba Lophatheri 10-15 part, Rhizoma Acori Graminei 10-15 part, Rhizoma Phragmitis 10-15 part, Radix Paeoniae Rubra 10-15 part, Radix Berberidis 5-10 part, Caulis Lonicerae 10-25 part, Fructus Leonuri 10-25 part, Semen Platycladi 10-30 part, Radix Camelliae sinensis 10-20 part, Herba Zornia Diphyllae 10-30 part, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 10-30 part, Radix Rhodiolae 5-10 part, Rhizoma Curcumae 5-10 part, Ramulus Mori 5-10 part, Herba Centellae 5-10 part, Caulis Spatholobi 15-30 part, Cortex Ilicis Rotundae 15-30 part, Radix Clematidis 5-15 part.
4. a kind of pharmaceutical composition for the treatment of apoplexy according to claim 1, is made up of the crude drug of following weight portion: 20 parts, Semen Persicae, Radix Salviae Miltiorrhizae 20 parts, Fructus Xanthii 15 parts, Semen Vaccariae 20 parts, Herba Lophatheri 13 parts, Rhizoma Acori Graminei 13 parts, Rhizoma Phragmitis 13 parts, Radix Paeoniae Rubra 13 parts, Radix Berberidis 8 parts, Caulis Lonicerae 18 parts, Fructus Leonuri 18 parts, Semen Platycladi 20 parts, Radix Camelliae sinensis 15 parts, Herba Zornia Diphyllae 20 parts, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 20 parts, Radix Rhodiolae 8 parts, Rhizoma Curcumae 8 parts, Ramulus Mori 7 parts, Herba Centellae 7 parts, Caulis Spatholobi 20 parts, Cortex Ilicis Rotundae 22 parts, Radix Clematidis 10 parts.
5. a kind of pharmaceutical composition for the treatment of apoplexy according to claim 1, is made up of the crude drug of following weight portion: 17 parts, Semen Persicae, Radix Salviae Miltiorrhizae 21 parts, Fructus Xanthii 12 parts, Semen Vaccariae 24 parts, Herba Lophatheri 11 parts, Rhizoma Acori Graminei 14 parts, Rhizoma Phragmitis 12 parts, Radix Paeoniae Rubra 15 parts, Radix Berberidis 6 parts, Caulis Lonicerae 23 parts, Fructus Leonuri 15 parts, Semen Platycladi 28 parts, Radix Camelliae sinensis 16 parts, Herba Zornia Diphyllae 27 parts, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 17 parts, Radix Rhodiolae 6 parts, Rhizoma Curcumae 9 parts, Ramulus Mori 5 parts, Herba Centellae 10 parts, Caulis Spatholobi 29 parts, Cortex Ilicis Rotundae 26 parts, Radix Clematidis 14 parts.
6. a kind of pharmaceutical composition for the treatment of apoplexy according to claim 1, is made up of the crude drug of following weight portion: 23 parts, Semen Persicae, Radix Salviae Miltiorrhizae 16 parts, Fructus Xanthii 18 parts, Semen Vaccariae 12 parts, Herba Lophatheri 14 parts, Rhizoma Acori Graminei 11 parts, Rhizoma Phragmitis 15 parts, Radix Paeoniae Rubra 10 parts, Radix Berberidis 8 parts, Caulis Lonicerae 12 parts, Fructus Leonuri 22 parts, Semen Platycladi 26 parts, Radix Camelliae sinensis 18 parts, Herba Zornia Diphyllae 27 parts, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 25 parts, Radix Rhodiolae 9 parts, Rhizoma Curcumae 8 parts, Ramulus Mori 10 parts, Herba Centellae 7 parts, Caulis Spatholobi 27 parts, Cortex Ilicis Rotundae 24 parts, Radix Clematidis 14 parts.
7. the pharmaceutical composition of the treatment apoplexy described in any one of claim 1-6, is characterized in that, adopts the conventional method of Chinese medicine preparation to be prepared into any traditional oral preparation.
8. the pharmaceutical composition for the treatment of apoplexy according to claim 7, is characterized in that, described oral formulations is capsule, pill, powder, tablet, granule.
CN201610017031.7A 2016-01-12 2016-01-12 Pharmaceutical composition for treating cerebral stroke Pending CN105477113A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610017031.7A CN105477113A (en) 2016-01-12 2016-01-12 Pharmaceutical composition for treating cerebral stroke

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610017031.7A CN105477113A (en) 2016-01-12 2016-01-12 Pharmaceutical composition for treating cerebral stroke

Publications (1)

Publication Number Publication Date
CN105477113A true CN105477113A (en) 2016-04-13

Family

ID=55664628

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610017031.7A Pending CN105477113A (en) 2016-01-12 2016-01-12 Pharmaceutical composition for treating cerebral stroke

Country Status (1)

Country Link
CN (1) CN105477113A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1583116A (en) * 2004-05-27 2005-02-23 董兆元 Chinese medicinal composition for diseases of nervus, varscular headache, cerebral blood supply lack and sequel of apolexy
CN101549035A (en) * 2009-04-21 2009-10-07 常熟雷允上制药有限公司 Medicament for treating cerebral thrombosis and sequela diseases and preparation method thereof
CN101628054A (en) * 2009-08-02 2010-01-20 李述岩 Medicine for treating ischemic cerebral apoplexy and its sequela

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1583116A (en) * 2004-05-27 2005-02-23 董兆元 Chinese medicinal composition for diseases of nervus, varscular headache, cerebral blood supply lack and sequel of apolexy
CN101549035A (en) * 2009-04-21 2009-10-07 常熟雷允上制药有限公司 Medicament for treating cerebral thrombosis and sequela diseases and preparation method thereof
CN101628054A (en) * 2009-08-02 2010-01-20 李述岩 Medicine for treating ischemic cerebral apoplexy and its sequela

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
蒋利魁: ""针药并用治疗缺血性中风63例临床观察"", 《光明中医》 *

Similar Documents

Publication Publication Date Title
CN102068682A (en) Chinese medicinal composition for treating digestive system diseases and preparation method thereof
CN104013929B (en) Rheumatism pain relief medicine for treating rheumatic arthritis and rheumatoid arthritis and preparation method thereof
CN101933973B (en) Medicament composition for preventing and treating liver damage
CN101129720B (en) Compound medicament for treating ankylosing spondylitis
CN101181383A (en) Medicine composition for treating apoplexy as well as preparation method
CN102198175A (en) Chinese medicine composition
CN101658636B (en) Chinese medical composition for treating coronary heart disease
CN104306662A (en) Traditional Chinese medicine composition for treating neurasthenia and preparation method thereof
CN101199606B (en) Medicament for treating liver disease
CN106511584A (en) Drug for treating postpartum fever
CN105477113A (en) Pharmaceutical composition for treating cerebral stroke
CN101549140B (en) Traditional Chinese medicine composition for treating AIDS and preparation method thereof
CN101579507B (en) Medicine for treating gall stones and preparation method thereof
CN101502597B (en) Medicament for treating stomachache and preparation method thereof
US20040071791A1 (en) Psoriasis treatment
CN108434422A (en) Chinese medicine composition and preparation method thereof for treating cardiovascular and cerebrovascular disease
CN103127413B (en) Pharmaceutical preparation for treating coronary diseases
CN103768454A (en) Composition for preventing and treating HIV/AIDS (Human Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome) and preparation method thereof
CN111700947B (en) Traditional Chinese medicine composition for treating ischemic stroke and application thereof
CN110841007B (en) Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof
CN101983712A (en) Novel medicament for treating coronary heart disease
CN106511539A (en) Application of Naoxintong traditional Chinese medicine composition in preparing blood sugar reducing drug
CN101569726A (en) Chinese medicament for treating fracture contusion
CN104758675A (en) Traditional Chinese medicine composition for treating migraine
CN105327279A (en) Traditional Chinese medicinal composition for treating leukemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160413

RJ01 Rejection of invention patent application after publication